Certuity LLC Buys New Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Certuity LLC purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 1,365 shares of the company’s stock, valued at approximately $214,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in KRYS. State Street Corp raised its position in shares of Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after purchasing an additional 119,936 shares during the period. Geode Capital Management LLC increased its stake in Krystal Biotech by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after purchasing an additional 11,411 shares in the last quarter. Franklin Resources Inc. raised its holdings in Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after buying an additional 62,178 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Krystal Biotech by 9.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company’s stock valued at $43,727,000 after buying an additional 19,777 shares in the last quarter. Finally, Braidwell LP grew its holdings in shares of Krystal Biotech by 57.4% during the third quarter. Braidwell LP now owns 168,691 shares of the company’s stock valued at $30,707,000 after buying an additional 61,512 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 14.10% of the company’s stock.

Krystal Biotech Stock Up 2.9 %

Shares of NASDAQ KRYS opened at $155.75 on Friday. The company has a market capitalization of $4.48 billion, a PE ratio of 87.99 and a beta of 0.84. The stock’s 50 day moving average price is $159.73 and its 200-day moving average price is $176.66. Krystal Biotech, Inc. has a twelve month low of $107.50 and a twelve month high of $219.34.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Chardan Capital restated a “buy” rating and issued a $212.00 target price on shares of Krystal Biotech in a report on Wednesday, December 18th. HC Wainwright reissued a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. Finally, Citigroup lifted their target price on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $206.67.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).